Knights of Columbus Asset Advisors LLC Purchases 27,260 Shares of Gilead Sciences, Inc. $GILD

Knights of Columbus Asset Advisors LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 94.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 56,123 shares of the biopharmaceutical company’s stock after purchasing an additional 27,260 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Gilead Sciences were worth $6,230,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Rothschild Investment LLC grew its holdings in shares of Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 84 shares during the last quarter. Hemington Wealth Management boosted its stake in Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares during the last quarter. Ignite Planners LLC increased its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares in the last quarter. Archer Investment Corp raised its stake in shares of Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Gilead Sciences by 0.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock valued at $3,912,000 after purchasing an additional 87 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $139.55 on Friday. The stock has a fifty day simple moving average of $125.05 and a two-hundred day simple moving average of $119.38. The firm has a market cap of $173.14 billion, a price-to-earnings ratio of 21.64, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $141.71. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.02 earnings per share. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wolfe Research raised its price target to $155 (from $150) and kept an “outperform” rating — implying ~10% upside from current levels. Wolfe Research PT Raise
• Positive Sentiment: Citigroup published a bullish forecast for strong price appreciation, supporting demand expectations for GILD. Citigroup Forecast
• Positive Sentiment: Truist Financial also issued a forecast calling for meaningful upside, lining up with broader analyst optimism. Truist Forecast
• Positive Sentiment: BMO Capital Markets added to the chorus of bullish forecasts, which reinforces analyst-driven buying interest. BMO Forecast
• Positive Sentiment: UBS reiterated expectations for upside, further supporting consensus that GILD’s fundamentals and pipeline justify higher valuations. UBS Note
• Positive Sentiment: Coverage pieces (BarChart, Zacks interest) note that Gilead has outperformed the market and that analysts are broadly optimistic — positive sentiment that can attract momentum flows. BarChart Analysts Overview
• Neutral Sentiment: Zacks flagged increased investor attention to GILD (tracking user searches), which can boost volume but is not a directional catalyst by itself. Zacks Attention Note
• Neutral Sentiment: Reported short-interest data is inconsistent (entries show increases but list 0 shares / NaN), suggesting a data glitch — no clear short-squeeze or heavy shorting signal from this report.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares at ~$139.89 (≈$1.4M), trimming his holding ~1.76%. Insider sales can be read negatively by some investors even if part of routine diversification. SEC Form 4

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wells Fargo & Company increased their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Truist Financial increased their target price on shares of Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. UBS Group boosted their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday. Argus increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $135.56.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the sale, the director owned 1,339 shares in the company, valued at $170,186.90. The trade was a 67.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 257,397 shares of company stock worth $33,385,512. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.